What treatment is there for enlarged liver in dogs

Dr Mayank Agarwal is a MD MD Gasteroloenterologist, he is a Gastro, Liver and Pancreas Specialist
Services
1. OPD consultation for the above mentioned problems
2. Upper GI endoscopy
3. colonoscopy
4. Sigmoidoscopy
5. Biopsy of suspicious endoscopic lesions
6. EVL Banding
7. Polypectomy
8. Esophageal structure dilatation
9. Esophageal stenting for cancer
10. ERCP for CBD stone
11. EUS
For appointment you can call him at 9085612000 or visit apolloclinicguwahati.com
Apollo Clinic, Kanchan Road, Opp Bora Service, Ulubari, Guwahati - 781007

Liver disease, in and of itself, is not contagious. If the Liver is diseased as a result of the Hepatitis C virus which IS contagious.... That's your answer. I hope that makes sense!
New medications for hepatitis are available now. Many people show no signs of the disease after the eight week treatment. Good luck!!

Yes, propylene Glycol or antifreeze is very dangerous for dogs. It tastes kind of sweet and they may drink it. According to PetMD: " less than three ounces (or 88 ml) of antifreeze is sufficient to poison a medium-sized dog. Antifreeze poisoning affects the brain, liver, and kidneys." This is why it can also cause seizures.

Hi Derek,
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Medical supervision during treatment is essential.
The level of serum folic acid should be observed during anticonvulsant therapy since Degranol may enhance the metabolism of folic acid.
Abnormalities of liver function and jaundice have been associated with long-term treatment.
Blood counts and liver function tests should be performed before commencing treatment.
Blood counts should then be repeated at weekly intervals during the first month of treatment and subsequently at monthly intervals; liver function tests should also be undertaken periodically, if allergic skin reactions occur, if the leucocyte and/or platelet count diminish, if tests reveal a deterioration in liver function, or if any serious adverse symptoms develop, Degranol should be withdrawn.
Reaction-time may be increased by Degranol. The patient's safety as a road-user or operator of machines may be impaired in consequence.
Unwanted effects - i.e. loss of appetite, dryness of the mouth, retching, diarrhoea or constipation, headache, drowsiness, dizziness, somnolence, ataxia, disorders of visual accommodation, diplopia, or, in elderly patients, states of confusion and agitation - may occur, particularly at the start of treatment. These effects may require temporary reduction in the dosage.
Hyponatraemia due to the antidiuretic effect of Degranol and possibly accompanied by vomiting, headache, and mental confusion has been observed.
Allergic skin reactions, as well as occurrences of exfoliative dermatitis, paraesthesia, systemic lupus erythematosus, Steven's-Johnson syndrome, photosensitivity, altered skin pigmentation, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, thrombo-embolism, left ventricular failure, disturbances of cardiac impulse conduction, hepatocellular and cholestatic hepatitis, acute oliguria with hypertension and proteinuria have been reported.
A wide variety of other central nervous system, gastro-intestinal, cardiovascular and dermatological effects have also been reported.
In patients with cardiovascular diseases, or with hepatic or renal disorders, glaucoma and in elderly subjects, Degranol should be administered with caution.
Tolerance may develop to some of the untoward effects of carbamazepine and they can be minimized by gradual increase in dosage and adjustment of maintenance dosage.
If treatment with Degranol is withdrawn abruptly, the change-over to another anti-epileptic should be effected under cover of diazepam or a barbiturate.

Hi Derek,

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Medical supervision during treatment is essential.
The level of serum folic acid should be observed during anticonvulsant therapy since Degranol may enhance the metabolism of folic acid.
Abnormalities of liver function and jaundice have been associated with long-term treatment.
Blood counts and liver function tests should be performed before commencing treatment.
Blood counts should then be repeated at weekly intervals during the first month of treatment and subsequently at monthly intervals; liver function tests should also be undertaken periodically, if allergic skin reactions occur, if the leucocyte and/or platelet count diminish, if tests reveal a deterioration in liver function, or if any serious adverse symptoms develop, Degranol should be withdrawn.
Reaction-time may be increased by Degranol. The patient's safety as a road-user or operator of machines may be impaired in consequence.
Unwanted effects - i.e. loss of appetite, dryness of the mouth, retching, diarrhoea or constipation, headache, drowsiness, dizziness, somnolence, ataxia, disorders of visual accommodation, diplopia, or, in elderly patients, states of confusion and agitation - may occur, particularly at the start of treatment. These effects may require temporary reduction in the dosage.
Hyponatraemia due to the antidiuretic effect of Degranol and possibly accompanied by vomiting, headache, and mental confusion has been observed.
Allergic skin reactions, as well as occurrences of exfoliative dermatitis, paraesthesia, systemic lupus erythematosus, Steven's-Johnson syndrome, photosensitivity, altered skin pigmentation, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, thrombo-embolism, left ventricular failure, disturbances of cardiac impulse conduction, hepatocellular and cholestatic hepatitis, acute oliguria with hypertension and proteinuria have been reported.
A wide variety of other central nervous system, gastro-intestinal, cardiovascular and dermatological effects have also been reported.
In patients with cardiovascular diseases, or with hepatic or renal disorders, glaucoma and in elderly subjects, Degranol should be administered with caution.
Tolerance may develop to some of the untoward effects of carbamazepine and they can be minimized by gradual increase in dosage and adjustment of maintenance dosage.
If treatment with Degranol is withdrawn abruptly, the change-over to another anti-epileptic should be effected under cover of diazepam or a barbiturate.

Usually, the symptoms of liver cancer do not show up until the later stages, but sometimes they may be observed sooner. There are certain common symptoms associated with this disease. They are:
1. Losing weight without even trying
2. Loss of appetite
3. An enlarged liver or spleen
4. Pain in the abdomen
5. Skin and eyes getting pale
6. Nausea or vomiting
Milk thistle diabetes would suggest some of the effective ways to get rid of the liver cancer.